The Future of Food: Major Opportunities for MustGrow and K+S! What is Next for Evotec After the Sell-Off?

MustGrow: When Will the Multibagger Story Take Off?

Food is one of the few sectors where demand is expected to grow almost independently of economic cycles over the long term. At the same time, a rapidly expanding global population is placing enormous pressure on agriculture. Farmers must produce more food while resources become increasingly scarce and environmental requirements continue to tighten.

This structural pressure has triggered a new wave of innovation. The market is looking for solutions that increase crop yields while reducing the use of chemicals, land, and energy. This is precisely where Canada's MustGrow Biologics has positioned itself with a portfolio of forward-looking products.

At the core of MustGrow's business model is the use of the naturally occurring properties of mustard plants. Mustard plants produce bioactive compounds that naturally protect against pests and harmful fungi. By harnessing these natural defense mechanisms, MustGrow has developed a scalable technology platform for biological crop protection and soil health solutions.

The company's innovation is protected by more than 100 patents and patent applications. The addressable market is enormous and continues to expand rapidly. Industry forecasts project the global regenerative agriculture market to reach approximately USD 50 billion by 2033.

The company's strategy revolves around two key product families. TerraSante™, MustGrow's mustard-derived organic biofertility product, supplies the soil microbiome with proteins and carbohydrates. Field trials have demonstrated a range of benefits, including improved soil health, greater water and nutrient efficiency, and significantly higher crop yields.

The second pillar is TerraMG™, a pre-registered natural crop protection product targeting soil-borne diseases and pests that attack plants through their root systems. In this market segment, MustGrow holds a significant strategic advantage through its exclusive license and collaboration agreement with Bayer. The German company has secured the development and commercialization rights for Europe, the Middle East, and Africa (EMEA), while MustGrow stands to receive additional milestone payments and royalty income once commercialization begins.

To support its next phase of growth, the company recently completed a capital increase through a non-brokered LIFE offering. Ultimately, CAD 3.7 million, almost twice the originally targeted amount, was raised. Shares are currently trading at around CAD 0.40, resulting in a market capitalization of approximately CAD 28 million. Analysts at GBC Research remain highly optimistic, assigning the stock a price target of CAD 2.70.

GBC analyst Matthias Greiffenberger commented: "In our view, MustGrow combines a clearly differentiated, mustard-based technology platform with exposure to the structurally growing market for biological agricultural solutions. TerraSante™, in particular, demonstrates that the technology is moving beyond the development stage into commercial-scale deployment. Most importantly, the added value for farmers is driven not only through sustainability but, above all, by improved product quality, healthier soils, potential yield gains, and a compelling economic return on investment."

K+S: Does EU Support Help?

The company is one of the world's leading producers of potash and salt products. Along with nitrogen and phosphorus, potassium is one of the three most important primary nutrients for crops. It regulates their water balance and improves their resistance to drought and disease.

In the long term, demand for potash is stable; in the short term, however, fertilizer prices are subject to high volatility. While high prices sometimes lead to record profits, when demand declines or abruptly stops, the pendulum swings in the opposite direction. Energy costs, geopolitical developments, and currency effects also play a role.

Recently, the EU announced that it would reimburse farmers suffering from rising fertilizer prices for the majority of the "additional" costs and make the funds available sooner. This could lead to a slight uptick in demand.

Currently, the shares are trading at around EUR 14, up about 10% since the start of the year. The volatile business performance is also reflected in the valuation multiples. In the current fiscal year, the P/E ratio is negative; for 2027, it stands at 13. Analysts have set an average price target of EUR 15.50, meaning the stock has only limited upside potential.

Evotec: Share Price Plunge After Another Major Profit Warning

Another profit warning sent Evotec shares tumbling more than 30% intraday, pushing the stock to its lowest level since 2016. The drug candidate developer for the pharmaceutical and biotech industries significantly lowered its annual targets due to revenue delays and weaker earnings. The company now expects an adjusted operating loss at the EBITDA level in the range of EUR 70 million to EUR 105 million. This is significantly lower than the previous guidance, which had projected an operating result in the range of EUR 0 to 40 million.

The revenue forecast was lowered to EUR 570 to 610 million, down from EUR 700 to 780 million. According to the company's announcement, approximately 85% of the revenue shortfall is attributable to milestone payments postponed until 2027 and to delays in partnership agreements currently under negotiation. After several profit warnings in recent years, however, investors are increasingly questioning the credibility of the company's forecasts.

The company's references to strong momentum in its core business have done little to reassure the market, despite first-half revenue in that segment increasing by approximately 28%. Management also reiterated that its "Horizon" transformation program remains on schedule. Analysts are now expected to revise their price targets following the latest warning. If the disappointing results are indeed largely the consequence of timing rather than lost business, the current share price could prove attractive.

MustGrow is positioned in several multi-billion-dollar growth markets. Its patented business model generates revenue streams, while its strategic partnership with Bayer provides significant long-term upside. Analysts have set a price target of CAD 2.70, implying substantial appreciation potential. For the volatile K+S share, however, analysts see only limited upside potential. Evotec, meanwhile, has suffered a major setback. While the company may be able to deliver stronger results next year, rebuilding investor confidence is likely to take considerably longer.